Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

T-DM1 and Non-pegylated Liposomal Doxorubicin in HER2-positive Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02562378
Recruitment Status : Completed
First Posted : September 29, 2015
Last Update Posted : January 8, 2019
Sponsor:
Collaborators:
Roche Pharma AG
Experior
Information provided by (Responsible Party):
MedSIR

Tracking Information
First Submitted Date  ICMJE September 17, 2015
First Posted Date  ICMJE September 29, 2015
Last Update Posted Date January 8, 2019
Study Start Date  ICMJE October 2015
Actual Primary Completion Date December 2018   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: September 25, 2015)
Dose Limiting Toxicities [ Time Frame: Baseline up to 6 weeks after patient entry ]
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: September 28, 2015)
  • Overall response rate [ Time Frame: Baseline up to 18 weeks after patient entry ]
    Patients with best overall response of confirmed complete response (CR) or partial response (PR) based on local investigator's assessment according to RECIST criteria guidelines (version 1.1)
  • Clinical Benefit Rate [ Time Frame: Baseline up to 18 weeks after patient entry ]
    Patients with a best overall response of complete response (CR) or partial response (PR) or stable disease (SD) based on local investigator's assessment according to RECIST criteria guidelines (version 1.1)
  • Progressions [ Time Frame: Baseline up to 18 weeks after patient entry ]
    Patients with progression. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or measurable increase in a non-target lesion, or the appearance of new lesions
  • Grade 3/4 adverse events, SAEs, deaths and discontinuations [ Time Frame: Baseline up to 18 weeks after patient entry ]
    Patients with grade 3/4 adverse events, SAEs, deaths and discontinuations
  • Level I cardiotoxicities [ Time Frame: Baseline up to 18 weeks after patient entry ]
    Sudden death (defined as within 24 hours; unexplained); Heart failure NYHA criteria class III-IV and LVEF decline defined as an absolute drop ≥10% resulting in a final LVEF <50%
  • Level II cardiotoxicities [ Time Frame: Baseline up to 18 weeks after patient entry ]
    Absolute drop ≥10% resulting in a final LVEF <50% and asymptomatic or heart failure NYHA criteria class II
  • Polymorphism of HER2 gene (SNP) [ Time Frame: Baseline ]
  • Plasma concentration (Cmax) [ Time Frame: Baseline up to 12 weeks after patient entry ]
  • Volum of distribution (Vd) [ Time Frame: Baseline up to 12 weeks after patient entry ]
  • Area under the plasma concentration versus time curve (AUC) [ Time Frame: Baseline up to 12 weeks after patient entry ]
  • Clearance (CL) [ Time Frame: Baseline up to 12 weeks after patient entry ]
  • Apparent half-life (t1/2) [ Time Frame: Baseline up to 12 weeks after patient entry ]
Original Secondary Outcome Measures  ICMJE
 (submitted: September 25, 2015)
  • Overall response rate [ Time Frame: Baseline up to 18 weeks after patient entry ]
    Patients with best overall response of confirmed complete response (CR) or partial response (PR) based on local investigator's assessment according to RECIST criteria guidelines (version 1.1)
  • Clinical Benefit Rate [ Time Frame: Baseline up to 18 weeks after patient entry ]
    Patients with a best overall response of complete response (CR) or partial response (PR) or stable disease (SD) based on local investigator's assessment according to RECIST criteria guidelines (version 1.1)
  • Progressions [ Time Frame: Baseline up to 18 weeks after patient entry ]
    Patients with progression
  • Grade 3/4 adverse events, SAEs, deaths and discontinuations [ Time Frame: Baseline up to 18 weeks after patient entry ]
    Patients with grade 3/4 adverse events, SAEs, deaths and discontinuations
  • Level I cardiotoxicities [ Time Frame: Baseline up to 18 weeks after patient entry ]
    Sudden death (defined as within 24 hours; unexplained); Heart failure NYHA criteria class III-IV and LVEF decline defined as an absolute drop ≥10% resulting in a final LVEF <50%
  • Level II cardiotoxicities [ Time Frame: Baseline up to 18 weeks after patient entry ]
    Absolute drop ≥10% resulting in a final LVEF <50% and asymptomatic or heart failure NYHA criteria class II
  • Polymorphism of HER2 gene (SNP) [ Time Frame: Baseline ]
  • Plasma concentration (Cmax) [ Time Frame: Baseline up to 12 weeks after patient entry ]
  • Volum of distribution (Vd) [ Time Frame: Baseline up to 12 weeks after patient entry ]
  • Area under the plasma concentration versus time curve (AUC) [ Time Frame: Baseline up to 12 weeks after patient entry ]
  • Clearance (CL) [ Time Frame: Baseline up to 12 weeks after patient entry ]
  • Apparent half-life (t1/2) [ Time Frame: Baseline up to 12 weeks after patient entry ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE T-DM1 and Non-pegylated Liposomal Doxorubicin in HER2-positive Metastatic Breast Cancer
Official Title  ICMJE Phase I Multicenter Clinical Trial Evaluating the Combination of Trastuzumab Emtansine (T-DM1) and Non-pegylated Liposomal Doxorubicin in HER2-positive Metastatic Breast Cancer
Brief Summary

The primary goal is to determine the maximum tolerated dose (MTD) of the combination of T-DM1 and non-pegylated liposomal doxorubicin in metastatic breast cancer (mBC) patients previously treated with taxanes and trastuzumab-based therapy.

In addition, pharmacokinetic data on the combination of T-DM1 and lyposomal doxorubicin will be obtained.

Detailed Description

Subjects: Age ≥ 18 years with HER2-positive metastatic breast cancer that have relapsed or progressed on or after taxanes and trastuzumab-based therapy. Subjects must have histologic or cytologic confirmation of the HER2-positive metastatic breast cancer. Evidence of measurable or evaluable metastatic disease is required.

Primary objective:

  • To determine the maximum tolerated dose (MTD) of the combination of T-DM1 and non-pegylated liposomal doxorubicin in metastatic breast cancer (mBC) patients previously treated with taxanes and trastuzumab-based therapy.

Secondary objectives:

  • To determine the efficacy of the combination of T-DM1 and non-pegylated liposomal doxorubicin, defined by the overall response rate (ORR), clinical benefit rate (CBR), number of progressions and number and reasons for deaths.
  • To assess the safety profile of the combination of T-DM1 and non-pegylated liposomal doxorubicin, defined by all toxicities reported during the study.
  • To evaluate the cardiac safety of the combination of T-DM1 and non-pegylated liposomal doxorubicin measured by LVEF as assessed by echocardiography, cardiac troponin I and B-type natriuretic peptide (BNP) levels.
  • To evaluate the potential role of single nucleotide polymorphisms (SNP) in the predisposition for developing cardiotoxicity.
  • To analyze the pharmacokinetics (PK) profile of T-DM1 and its metabolites and non-pegylated liposomal doxorubicin.

Type of study: This is a prospective dose-finding, multicenter and open-label phase I clinical trial.

Treatment: Trastuzumab emtansine (T-DM1) will be administered at a fixed dose of 3.6 mg/kg IV on Day 1 every 3 weeks and three cohorts of patients with three different dose levels of conventional non-pegylated liposomal doxorubicin (45 mg/m2, 50 mg/m2 and 60 mg/m2) IV on Day 1 in cycles of 21 days each are planned.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Breast Cancer
Intervention  ICMJE Drug: Trastuzumab and non-pegylated liposomal doxorubicin
Trastuzumab 3.6 mg/kg IV on Day 1 every 3 weeks and non-pegylated liposomal doxorubicin (45 mg/m2, 50 mg/m2 and 60 mg/m2) IV
Other Name: T-DM1 and non-pegylated liposomal doxorubicin
Study Arms  ICMJE Experimental: Trastuzumab + doxorubicin
Trastuzumab and non-pegylated liposomal doxorubicin: Trastuzumab 3.6 mg/kg IV on Day 1 every 3 weeks and non-pegylated liposomal doxorubicin (45 mg/m2, 50 mg/m2 and 60 mg/m2) IV
Intervention: Drug: Trastuzumab and non-pegylated liposomal doxorubicin
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: January 4, 2019)
15
Original Estimated Enrollment  ICMJE
 (submitted: September 25, 2015)
24
Actual Study Completion Date  ICMJE December 2018
Actual Primary Completion Date December 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Signed informed consent
  • Patient able and willing to comply with protocol
  • Cytologically or histologically confirmed carcinoma of the breast.
  • Incurable locally advanced or metastatic disease who have previously received up to two previous chemotherapy regimens in this setting. Patient must have progressed or relapsed on or after taxane and trastuzumab-based therapy.
  • HER2-positive disease
  • At least one measurable lesion according to RECIST version 1.1; or patients with non measurable lesions could be included with these exceptions:

    o patients with only blastic bone lesions / with only pleural, peritoneal or cardiac effusion, or meningeal carcinomatosis

  • ≥ 18 years of age
  • ECOG 0 or 1
  • Life expectancy ≥ 3 months
  • Adequate bone marrow function:

    • Hemoglobin ≥ 10 g/dl.
    • Absolute neutrophil count ≥ 1.5 x 109/L.
    • Platelets ≥ 100 x 109/L without transfusions within 21 days
    • International normalized ratio (INR) < 1.5 × the upper limit of normal (ULN).
  • Adequate hepatic and renal function
  • Adequate cardiovascular function with LVEF ≥ 55%
  • Recovery from all reported toxicities of previous anti-cancer therapies to baseline or grade ≤ 1 (CTCAE version 4.0), except for alopecia
  • For women of childbearing potential and not postmenopausal, and who have not undergone surgical sterilization with a hysterectomy and/or bilateral oophorectomy, and men with partners of childbearing potential, use of forms of contraception

Exclusion Criteria:

  • Previous treatment with T-DM1 or anthracyclines
  • More than two chemotherapeutic regimens for locally advanced incurable disease or metastatic disease
  • Prior anti-cancer treatment with chemotherapy, immunotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin-C), hormonal therapy or lapatinib within 7 days, prior trastuzumab within 21 days (7 days if weekly trastuzumab) or any other targeted therapy within the last 21 days prior to starting study treatment
  • Previous radiotherapy for the treatment of unresectable, locally advanced/recurrent or mBC is not allowed if:

    • The last fraction of radiotherapy has been administered within 21 days prior to first study drug administration (except for brain irradiation; at least 28 days will be required)
    • More than 25% of marrow-bearing bone has been irradiated
  • History of intolerance (including Grade 3 or 4 infusion reaction) or hypersensitivity to the active substance or to any of the excipients of T-DM1 or non-pegylated liposomal doxorubicin
  • Patients with CNS involvement. However, patients with metastatic CNS tumors may participate in this trial if the patient is > 4 weeks from radiotherapy completion, is clinically stable with respect to CNS tumor at the time of study entry and is not receiving steroid therapy for brain metastases
  • Severe/uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Cardiopulmonary dysfunction
  • Current peripheral neuropathy of Grade ≥ 3 per the NCI CTCAE, v4.0
  • History of a decrease in LVEF to < 40% or symptomatic CHF with previous trastuzumab treatment
  • Prior malignancy, other than carcinoma in situ of the cervix, or non-melanoma skin cancer, unless the prior malignancy was cured ≥ 5 years before first dose of study drug with no subsequent evidence of recurrence
  • Current known active infection with HIV, hepatitis B, and/or hepatitis C virus
  • Women who are pregnant or breast-feeding
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE France,   Spain
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02562378
Other Study ID Numbers  ICMJE Medopp038
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party MedSIR
Study Sponsor  ICMJE MedSIR
Collaborators  ICMJE
  • Roche Pharma AG
  • Experior
Investigators  ICMJE
Study Director: Javier Cortés, MD Hospital Ramon y Cajal, Madrid, Spain
PRS Account MedSIR
Verification Date December 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP